OncoCyte Statistics
Total Valuation
OncoCyte has a market cap or net worth of $20.35 million. The enterprise value is $12.09 million.
| Market Cap | 20.35M |
| Enterprise Value | 12.09M |
Important Dates
The last earnings date was Friday, April 12, 2024, before market open.
| Earnings Date | Apr 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
OncoCyte has 8.27 million shares outstanding. The number of shares has increased by 38.10% in one year.
| Shares Outstanding | 8.27M |
| Shares Change (YoY) | +38.10% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 20.64% |
| Owned by Institutions (%) | 86.16% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.54 |
| Forward PS | 10.23 |
| PB Ratio | 0.99 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.49, with a Debt / Equity ratio of 0.14.
| Current Ratio | 1.49 |
| Quick Ratio | 1.61 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -533.25 |
Financial Efficiency
Return on equity (ROE) is -82.30% and return on invested capital (ROIC) is -107.71%.
| Return on Equity (ROE) | -82.30% |
| Return on Assets (ROA) | -35.20% |
| Return on Capital (ROIC) | -107.71% |
| Revenue Per Employee | $34,953 |
| Profits Per Employee | -$667,977 |
| Employee Count | 43 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.58% in the last 52 weeks. The beta is 0.78, so OncoCyte's price volatility has been lower than the market average.
| Beta (1Y) | 0.78 |
| 52-Week Price Change | -53.58% |
| 50-Day Moving Average | 2.91 |
| 200-Day Moving Average | 3.22 |
| Relative Strength Index (RSI) | 31.16 |
| Average Volume (30 Days) | 56,538 |
Short Selling Information
The latest short interest is 179,137, so 2.17% of the outstanding shares have been sold short.
| Short Interest | 179,137 |
| Short Previous Month | 178,285 |
| Short % of Shares Out | 2.17% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 14.86 |
Income Statement
In the last 12 months, OncoCyte had revenue of $1.50 million and -$28.72 million in losses. Loss per share was -$3.75.
| Revenue | 1.50M |
| Gross Profit | 413,000 |
| Operating Income | -25.14M |
| Pretax Income | -27.78M |
| Net Income | -28.72M |
| EBITDA | -26.05M |
| EBIT | -27.73M |
| Loss Per Share | -$3.75 |
Balance Sheet
The company has $11.13 million in cash and $2.87 million in debt, giving a net cash position of $8.26 million or $1.00 per share.
| Cash & Cash Equivalents | 11.13M |
| Total Debt | 2.87M |
| Net Cash | 8.26M |
| Net Cash Per Share | $1.00 |
| Equity / Book Value | 20.47M |
| Book Value Per Share | 2.47 |
| Working Capital | 3.50M |
Cash Flow
In the last 12 months, operating cash flow was -$23.33 million and capital expenditures $73,000, giving a free cash flow of -$23.25 million.
| Operating Cash Flow | -23.33M |
| Capital Expenditures | 73,000 |
| Free Cash Flow | -23.25M |
| FCF Per Share | -$3.04 |
Margins
Gross margin is 27.48%, with operating and profit margins of -1,672.39% and -1,911.04%.
| Gross Margin | 27.48% |
| Operating Margin | -1,672.39% |
| Pretax Margin | -1,848.37% |
| Profit Margin | -1,911.04% |
| EBITDA Margin | -1,733.13% |
| EBIT Margin | -1,844.91% |
| FCF Margin | -1,547.04% |
Dividends & Yields
OncoCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.10% |
| Shareholder Yield | -38.10% |
| Earnings Yield | -141.13% |
| FCF Yield | -114.25% |
Analyst Forecast
The average price target for OncoCyte is $4.06, which is 65.04% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.06 |
| Price Target Difference | 65.04% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 25, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jul 25, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
OncoCyte has an Altman Z-Score of -6.32 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.32 |
| Piotroski F-Score | 4 |